AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$TELA

Capper Joseph H purchased $78K of TELA

Capper Joseph H purchased 75,000 shares of TELA Bio, Inc. (TELA) at an average of $1.05 ($1.02–$1.06) across 2 trades over 2026-09-14 to 2026-09-15.

Original reporting
SEC EDGAR · Capper Joseph H
Published Sep 16, 2026, 10:46 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 10:52 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TELA
Neutral
medium confidence
Mentioned
$TELA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TELANeutralLow
01

Why it matters

The disclosed purchase is modest and unlikely to move the stock materially.

02

Market read

Minor insider transaction with limited trading relevance.

03

What to watch

Potential upcoming clinical data or financing events not disclosed.

Relevance 4/10Novelty 3/10Timing: filed today

Background

Form 4 disclosures provide the first public record of insider trades.

Company-level read

Ticker impact

$TELANeutralMedium confidence
Context

Director Capper Joseph H bought 75,000 shares for $78K in a Form 4 filing.

Expected impact

Minimal short-term price movement expected.

Evidence & confidence

Purchase size is modest relative to float; no immediate trading signal.

Market effects

Sector

None significant for biotech sector.

Regional

No regional effect.

Global

Limited to TELA shareholders.

Counterpoint

What could challenge this read

Insider buying could be a subtle bullish sign despite small size.

Key entities

  • Director
    Capper Joseph H

    Insider making a $78K purchase of TELA shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TELA insider trading history →

Related articles

$TELAMed

TELA Bio Reports Third Quarter 2026 Financial Results

TELA Bio, Inc. (TELA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 TELA Bio Reports Third Quarter 2026 Financial Results Reduced sequential operating loss by 21%, including cost of realignment MALVERN, PA, November 10, 2026 -- TELA Bio, Inc. (“TELA Bio”), a comme rcial-stage medical technology company focused on providing innovative

SEC EDGAR 8-K
$TELAMed

TELA Bio (TELA) Q2 2026 Earnings Call Transcript

TELA Bio reported Q2 2026 revenue of $19.3M, down 4% YoY, driven by declines in OviTex PRS unit volumes and price-mix headwinds. International revenue grew 26% YoY, while gross margin improved to 72%. Net loss was $11.3M, and cash reserves decreased to $30.4M. Management cited competitive pressures and slower sales rep productivity as challenges, while highlighting market share gains in hernia products and plans to reduce costs.

fool.com